Radiotherapie complicaties: Xerostomie dry-mouth syndrome xerostomia
Conditions
Interventions
A reduction of the radiation dose specifically in the part of the parotid gland
where most of its stem cells reside.
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients treated with planned curative primary radiotherapy for HNC, with or without chemotherapy or cetuximab meeting the following criteria: - Squamous cell carcinoma originating from the mucosa of the head and neck area or nasofaryngeal carcinoma originating from the nasofarynx; - The radiotherapy includes prophylactic or therapeutic irradiation of both sides of the neck (at least level II to IV); - Age * 18 years; - WHO performance 0-2; - pre-treatment stimulated parotid gland saliva production >0.2 ml/min.
Exclusion criteria
Exclusion criteria: - Postoperative radiotherapy; - Re-irradiation; - Unilateral radiotherapy; - Primary salivary gland tumours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of parotid gland dysfunction (reduction of saliva production to less than 25% of the production pre-radiotherapy.) | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician-rated xerostomia (CTCAE v4.0) GRIX questionnaire (Groningen Radiation Induced Xerostomia questionnaire) Patient-rated xerostomia (questionnare EORTC QLQ-H&N35) | — |
Countries
Netherlands
Outcome results
None listed